What is first-line therapy for status epilepticus in adults?

Benzodiazepines (lorazepam, midazolam, or diazepam, chosen by route of access) are the recommended first-line pharmacologic treatment for status epilepticus in adults, with trial evidence supporting IV lorazepam/diazepam and IM midazolam as similarly effective options; second-line agents (fosphenytoin, valproate, levetiracetam) are used if benzodiazepines fail.

First-line pharmacologic treatment

• Benzodiazepines are recommended as first-line therapy for status epilepticus in adults, with lorazepam, midazolam, and diazepam most recommended; this is echoed by the German Society of Neurology guideline for status epilepticus in the COVID-19 context, which states benzodiazepines are usually given first.
• Route depends on access: intravenous lorazepam is preferred when IV/IO access is available, intramuscular midazolam is used when it is not, and rectal diazepam is an option if neither IV/IO nor IM access is feasible.

Trial evidence on first-stage treatment efficacy

• A systematic review of four RCTs (1234 adults) found intravenous lorazepam and intravenous diazepam given by paramedics were more effective than placebo, and intramuscular midazolam was non-inferior to intravenous lorazepam.
• Median time to seizure cessation from drug administration varied from 2 to 15 minutes across the included RCTs.
• Rates of respiratory depression among participants receiving active treatments ranged from 6.4% to 10.6%, and mortality ranged from 2% to 7.6% in active treatment groups versus 6.2% to 15.5% in control groups.
• The ESETT trial found no difference in efficacy between fosphenytoin, valproate, and levetiracetam as second-line agents after benzodiazepine failure, with these drugs aborting status epilepticus within an hour in nearly 50% of patients.

Dosing of benzodiazepine agents

• Reported dosing options include lorazepam 0.1 mg/kg IV (maximum dose 4 mg), diazepam 0.2 mg/kg IV (maximum 8 mg), and midazolam 10 mg for patients >40 kg, 5 mg for 13–40 kg, or 0.2 mg/kg for weight <12 kg.

Safety considerations with benzodiazepine therapy

• Benzodiazepine therapy carries a risk of respiratory depression, with potential need for intubation with repeated dosing, per the Neurocritical Care Society's Status Epilepticus Guideline Writing Committee discussion.
• More than two doses of benzodiazepines increases the risk of respiratory depression.
• Clinicians must monitor for adverse effects like respiratory depression and sedation with repeated dosing, which may necessitate airway management, and first-line treatments are often underdosed due to fear of complications.

Sources

• Review of Levetiracetam as a First Line Treatment in Status Epilepticus in the Adult Patients – What Do We Know so Far? — Frontiers in Neurology
• Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence — Journal of Neurology
• “Neurological manifestations of COVID-19” - guideline of the German society of neurology — Neurological Research and Practice
• Blog and Podcast Watch: Neurologic Emergencies — Western Journal of Emergency Medicine
• Pearls and Pitfalls of Introducing Ketogenic Diet in Adult Status Epilepticus: A Practical Guide for the Intensivist — Journal of Clinical Medicine
• Between the retirement of phenytoin and the crowning of levetiracetam: balancing innovation, safety, accessibility and well-established practices — Arquivos de Neuro-Psiquiatria
• Target Trial Emulation Meta-Analysis of Benzodiazepines For Out-of-Hospital Status Epilepticus in Adults — Evidance health sciences
• The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy — Frontiers in Pharmacology
• Diagnosis, treatment, and outcome prediction of non-convulsive status epilepticus in unconscious patients in intensive care units — Neurological Research and Practice
• Predictors of outcome in refractory generalized convulsive status epilepticus — Epilepsia Open

Decision support for clinicians, not medical advice. Answers are grounded in the published literature and every claim cites its source in the interactive view.